OrbiMed’s State Street Health Care Select Sector SPDR ETF XLV Stock Holding History

OrbiMed’s Portfolio XLV Stock Details XLV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-113,200	Closed	-$10M	–	158
2020 Q1	$10M	Hold	113,200	–	–	0.17%	87
2019 Q4	$11.5M	Buy	+113,200	New	+$10.9M	0.16%	80

Other funds holding XLV

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NLI

Nippon Life Insurance Tokyo, Japan $6.04B AUM 4.21% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

OrbiMed's XLV Position: Q2 2020 in Review

OrbiMed sold out of State Street Health Care Select Sector SPDR ETF (XLV) in Q2 2020, closing a stake of 113,200 shares — an estimated $10M sold.

OrbiMed first reported a position in XLV in Q4 2019 and held it in 2 quarters. The position peaked at $11.5M in Q4 2019. 1,051 funds tracked by Wall St. Rank hold XLV as of Q2 2020.

OrbiMed reported no remaining State Street Health Care Select Sector SPDR ETF position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 113,200 State Street Health Care Select Sector SPDR ETF shares in Q2 2020, an estimated $10M.
OrbiMed first reported a position in State Street Health Care Select Sector SPDR ETF in Q4 2019 and held it in 2 quarters.
OrbiMed's State Street Health Care Select Sector SPDR ETF position peaked at $11.5M in Q4 2019.
1,051 funds tracked by Wall St. Rank held State Street Health Care Select Sector SPDR ETF as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.